Human Milk Oligosaccharides (HMO) is an intricate bioactive sugar molecule present in human milk. It functions as growth substrates for particular beneficial bacteria. Due to being structurally complex and diverse, extracting or synthesizing them for use in the formula is challenging. As human milk oligosaccharides (HMO) is beneficial for micro biome and immunity, hence, many new techniques are getting researched and developed by the key player which include extracting HMO from cow milk, practicing expensive techniques (chemically or enzymatically synthesizing) or using microbes to produce them.
Request for sample here: “Global Human Milk Oligosaccharides Market”
Human Milk Oligosaccharides (HMO) products are expensive because a large amount of human milk is to be synthesized to achieve a handful of HMO. Hence as a remedy, extracting and synthesizing techniques are improving. It act as prebiotics in the human body and help maintain gut health. They promote bacterial growth, especially bifido bacteria genus, in the gut, which helps improve metabolic activity. The primary functions of human milk oligosaccharides include the prevention of infection, the supply of sialic acid for brain development, and prebiotic effects. Infant formula which has been supplemented with HMOs like 2′fucosyllactose, lacto-N-neotetraose, and 2 oligosaccharides have been studied by the FDA and have been recommended as safe, well-tolerated, and supports age-appropriate growth for infants. The “Global Human Milk Oligosaccharides Market” is accounted for $17.90 million in 2018 and is expected to reach $98.05 million by 2027 growing at a CAGR of 21%.
Rising focus on the development of cost effectual production techniques has opened avenues for innovation in the human milk oligosaccharides (HMO) area which is expected to create growth opportunities in the human milk oligosaccharides (HMO) market for the industry players. This area has a lot of extent for improvement and innovation, as no such cost-effective technique is obtainable in the market till date. Hence, the manufacturers can attain a competitive edge in the market through innovation and technological advancement. Moreover, recent years have witnessed various developments in the infant formula space with prominent end-use companies launching new and innovative products. For instance, in April 2019, Nestlé S.A., a Switzerland-based food and beverage company, introduced three new products in U.K., namely, SMA Advanced Follow-on Formula, SMA Advanced Growing up Milk, and SMA Advanced Infant Formula.
Request for customization here: “Global Human Milk Oligosaccharides Market”
These products contained artificial HMOs and were intended for infants who were not breastfed. Such developments within the infant formula sector are likely to drive the demand for human milk oligosaccharides in near future. While food and nutrition sciences continue to evolve and converge on health-related end points, future innovations in infant foods will include a focus on identification of novel, bioactive ingredients, preparations and/or delivery systems during the sustained study of human milk composition, functionality and feeding practices. Continued technological advancement is required in ingredient technology, processing and packaging strategies to better mimic human milk composition, bioavailability of bioactive components and ultimate functionality of infant formula and foods. In all cases, innovation will continue to require a balance between technological progress and assessment of both efficacy and safety of novel ingredients, platforms and finished product concepts.
For more information fill in the Inquiry form at: “Global Human Milk Oligosaccharides Market”
North America human milk oligosaccharides (HMO) market is expected to have considerable growth during the forecast period, due to increasing disposable incomes, new product innovations. The presence of numerous prominent infant formula and baby food manufacturers along with technological advancements are expected to boost the regional market growth in the forthcoming years. North America has registered an increased demand for donor human milk. On the other hand, there exist only 11 milk banks in countries such as Canada and the U.S., which is actually not sufficient to meet the increasing demand for donor milk. This factor will increase the usage of HMO in the infant formula in order to provide proper nutrition to the babies. United States is one of leading country in this region, due to increasing customer awareness in the region; about the health benefits of HMO in infant nutrition is one of the key factors aiding the market to grow further in the country with various product launches. For instance, in 2016, 2’-fucosyllactose was produced by Jennewein Biotechnologies GmbH, for the first time as a food-grade quality product to meet the demand of the US infant formula market. With the rise in inclusion of HMO in prebiotics as it helps in developing commensal bacteria and the increasing demand for functional food and beverages, and the dietary supplements for better health and digestion, the market for HMO is expected to grow in the region.
0 Comments